EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: A potential mechanism of EGFR-driven antagonism of apoptosis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1476-4598

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: A potential mechanism of EGFR-driven antagonism of apoptosis ; volume:10 ; number:1 ; day:9 ; month:3 ; year:2011 ; pages:1-13 ; date:12.2011
Molecular cancer ; 10, Heft 1 (9.3.2011), 1-13, 12.2011

Creator: Cao, Xinyu
Zhu, Hu
Ali-Osman, Francis
Lo, Hui-Wen

Contributor: SpringerLink (Online service)

DOI: 10.1186/1476-4598-10-26

URN: urn:nbn:de:101:1-2021082207482739127518

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:02 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Cao, Xinyu
Zhu, Hu
Ali-Osman, Francis
Lo, Hui-Wen
SpringerLink (Online service)

Other Objects (12)

EGFR-TKIs resistance via EGFR-independent signaling pathways

Hochschulschrift

Der Einfluss der EGFR Expressionsdichte auf die EGFR Antikörper gerichteten Abwehrmechanismen

Hochschulschrift

The Role of EGFR

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

EGFR signaling in lung fibrosis

Hochschulschrift

EGFR-Polymorphismen beim kolorektalen Karzinom

Hochschulschrift

Prognostische Bedeutung von E-Cadherin, β-Catenin [Beta-Catenin], EGFR, pEGFR Y1068, pEGFR Y1086 und Ki-67 im Barrett-Karzinom

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

EGFR-TKIs resistance via EGFR-independent signaling pathways

Hochschulschrift

Der Einfluss der EGFR Expressionsdichte auf die EGFR Antikörper gerichteten Abwehrmechanismen

Hochschulschrift

The Role of EGFR

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

EGFR signaling in lung fibrosis

Hochschulschrift

EGFR-Polymorphismen beim kolorektalen Karzinom

Hochschulschrift

Prognostische Bedeutung von E-Cadherin, β-Catenin [Beta-Catenin], EGFR, pEGFR Y1068, pEGFR Y1086 und Ki-67 im Barrett-Karzinom

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

EGFR-TKIs resistance via EGFR-independent signaling pathways

Hochschulschrift

Der Einfluss der EGFR Expressionsdichte auf die EGFR Antikörper gerichteten Abwehrmechanismen

Hochschulschrift

The Role of EGFR

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

EGFR signaling in lung fibrosis

Hochschulschrift

EGFR-Polymorphismen beim kolorektalen Karzinom

Hochschulschrift

Prognostische Bedeutung von E-Cadherin, β-Catenin [Beta-Catenin], EGFR, pEGFR Y1068, pEGFR Y1086 und Ki-67 im Barrett-Karzinom

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: A potential mechanism of EGFR-driven antagonism of apoptosis

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

EGFR-TKIs resistance via EGFR-independent signaling pathways

Der Einfluss der EGFR Expressionsdichte auf die EGFR Antikörper gerichteten Abwehrmechanismen

The Role of EGFR

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

EGFR signaling in lung fibrosis

EGFR-Polymorphismen beim kolorektalen Karzinom

Prognostische Bedeutung von E-Cadherin, β-Catenin [Beta-Catenin], EGFR, pEGFR Y1068, pEGFR Y1086 und Ki-67 im Barrett-Karzinom

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

EGFR-TKIs resistance via EGFR-independent signaling pathways

Der Einfluss der EGFR Expressionsdichte auf die EGFR Antikörper gerichteten Abwehrmechanismen

The Role of EGFR

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

EGFR signaling in lung fibrosis

EGFR-Polymorphismen beim kolorektalen Karzinom

Prognostische Bedeutung von E-Cadherin, β-Catenin [Beta-Catenin], EGFR, pEGFR Y1068, pEGFR Y1086 und Ki-67 im Barrett-Karzinom

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

EGFR-TKIs resistance via EGFR-independent signaling pathways

Der Einfluss der EGFR Expressionsdichte auf die EGFR Antikörper gerichteten Abwehrmechanismen

The Role of EGFR

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

EGFR signaling in lung fibrosis

EGFR-Polymorphismen beim kolorektalen Karzinom

Prognostische Bedeutung von E-Cadherin, β-Catenin [Beta-Catenin], EGFR, pEGFR Y1068, pEGFR Y1086 und Ki-67 im Barrett-Karzinom

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Related objects

Reset password